[The kinetics of sulfamerazine (Mebacid) and the effect of sulfamerazine therapy on p-aminohippuric acid clearance in pregnancy].
Elimination half-life of Sulfamerazin (Mebacid) was not different in pregnant and non-pregnant women after a single oral dose and after 11 days repeated administration in therapeutic dosis. The initial concentrations of Sulfamerazin are lower in pregnants than in non-pregnants. Elimination half-life of p-aminohippurate (PAH) is shortened by Sulfamerazin-pretreatment, renal excretion of PAH is increased respectively.